登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次业绩说明会以网络文字互动形式召开，公司将针对2025年第三季度的经营成果、财务状况及发展战 略与投资者进行互动交流和沟通，在信息披露允许的范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （三）会议召开方式：网络文字互动 三、参加人员 ● 会议召开时间：2025年12月4日（星期四）下午15:00-16:00 ● 投资者可于2025年11月28日（星期五）至12月3日（星期三）16:00前登录上证路演中心网站首页点 击"提问预征集"栏目（https://roadshow.sseinfo.com/preCallQa）或通过四川百利天恒药业股份有限公司 （以下简称"公司"）邮箱ir@baili-pharm.com进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 公司已于2025年10月27日发布公司2025年第三季度报告，为便于广大投资者更全面深入地了解公司2025 年第三季度经营 ...

证券代码：688506 证券简称：百利天恒 公告编号：2025-087 四川百利天恒药业股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2025 年 11 月 28 日（星期五）至 12 月 3 日（星期三）16:00 前 登 录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 （https://roadshow.sseinfo.com/preCallQa）或通过四川百利天恒药业股份有限公司 （以下简称"公司"）邮箱 ir@baili-pharm.com 进行提问。公司将在说明会上对 投资者普遍关注的问题进行回答。 公司已于 2025 年 10 月 27 日发布公司 2025 年第三季度报告，为便于广大投 资者更全面深入地了解公司 2025 年第三季度经营成果、财务状况及发展战略， 公司计划于 2025 年 12 月 4 日（星期四）下午 15:00-16:00 举行 2025 年第三季度 业绩说明 ...

证券日报网讯百利天恒11月25日在互动平台回答投资者提问时表示，截至2025年9月30日，股东户数为 5，979户。 ...

Core Viewpoint - The innovative drug Iza-bren developed by Baillie Tianheng has received formal acceptance for its market application, marking it as the world's first EGFR×HER3 dual-target ADC to enter the III clinical phase, which is expected to accelerate its market launch [2][4]. Group 1: Drug Development and Clinical Trials - Iza-bren is currently undergoing over 40 clinical trials in China and the United States for various tumor types, specifically targeting locally advanced or metastatic nasopharyngeal carcinoma [2][5]. - The drug has been included in the priority review list by the National Medical Products Administration (NMPA) based on interim analysis results from the BL-B01D1-303 study [4][5]. - Iza-bren has seven indications recognized as breakthrough therapy by the NMPA and one by the U.S. FDA [5]. Group 2: Research and Development Investment - Baillie Tianheng has significantly increased its R&D investment from CNY 196 million in 2020 to CNY 1.443 billion in 2024, with a total of CNY 4.811 billion invested over the past six years [3][9]. - In the first three quarters of 2025, the company’s R&D expenditure reached CNY 1.772 billion, surpassing the total for 2024, reflecting a year-on-year growth of 90.23% [9][10]. - The company employs 1,360 R&D personnel, accounting for 48.16% of its total workforce, with a notable increase in staff with master's degrees or higher [10]. Group 3: Financial Performance and Market Response - Baillie Tianheng's stock price has doubled since the beginning of 2025, with a significant increase from CNY 24.70 per share at the time of its IPO to approximately CNY 384.97 per share by November 2025, representing a cumulative increase of over 14 times [10]. - The company experienced a substantial revenue increase in 2024, reaching CNY 5.823 billion, a 936.31% year-on-year growth, primarily due to a collaboration agreement with Bristol-Myers Squibb [7][10].

Core Insights - The innovation drug sector in China is experiencing a strong upward trend driven by policy, industry dynamics, demand, and globalization, with expectations for continued growth into 2026 [1][2] Group 1: Market Performance - As of November 24, 2025, the CSI Innovation Drug Industry Index rose by 0.82%, with notable increases in stocks such as Zai Lab (up 4.64%) and Kelun Pharmaceutical (up 2.47%) [1] - The index reflects the performance of up to 50 representative listed companies involved in innovative drug research and development [2] Group 2: Regulatory Developments - Baili Tianheng announced that it received a formal acceptance notice from the National Medical Products Administration for its first-in-class EGFR×HER3 dual antibody ADC drug, which is now in Phase III clinical trials [1] Group 3: Industry Outlook - Citic Construction Investment Securities highlights that the Chinese pharmaceutical industry is entering a critical phase of "innovation realization and global layout," supported by population and domestic demand, as well as manufacturing capabilities [2] - The industry is expected to focus on internal supply chain security and compliance while exploring diversified international expansion [2] - The outlook for 2026 includes opportunities from innovation commercialization, global breakthroughs, policy optimization, and industry mergers and acquisitions [2]

Group 1: Industry Highlights - The domestic first large-capacity all-solid-state battery production line has been completed and is currently in small-batch testing, with reports indicating that it will be installed in vehicles by 2027, making 1000 km range for electric vehicles a possibility [4] - The Federal Reserve is managing interest rate cut expectations, with two officials calming the market after a significant drop, indicating a 69% probability of a rate cut in December, leading to a rebound in US stocks [5] - The lithium carbonate futures price has surged recently, prompting CATL to plan the earliest restart of an important lithium mine in Yichun next month, with significant gains in related market concept stocks [5] Group 2: Company Developments - Baillie Tianheng's self-developed dual-antibody ADC drug, iza-bren, has had its market application accepted, aimed at treating locally advanced or metastatic nasopharyngeal carcinoma [7] - Huawei has released Flex:ai AI container software, which utilizes computing power slicing technology to divide a single GPU/NPU computing power card into multiple virtual computing units, enabling simultaneous support for multiple AI workloads [8] - Longxin Storage has launched DDR5 and LPDDR5X memory products, with both product series reportedly ranking at the top tier in terms of speed and capacity in the industry [8] - JinkoSolar's Tiger 3 modules have officially entered mass production, with global orders reaching 15 GW [8] - Chang'an Automobile plans to gradually release prototype vehicles starting next year and will launch its first vehicle-mounted component robot in the first quarter of next year [8] - The company Nenghui Technology signed a contract with Company X for a total estimated price of 10 million yuan for new energy power battery assembly [8] - Guotai Microelectronics' major shareholder and its concerted actors plan to reduce their holdings by no more than 2.24% [8]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 登录新浪财经APP 搜索【信披】查看更多考评等级 近日，四川百利天恒药业股份有限公司（以下简称"公司"）收到国家药品监督管理局核准签发的《受理 通知书》，公司自主研发的全球首创（First-in-class）、新概念（New concept）且唯一进入III期临床阶 段的EGFR×HER3双抗ADC（iza-bren）的药品上市申请（NDA）已获得正式受理。 本次受理是基于BL-B01D1-303研究的期中分析结果。此前，公司已与国家药品监督管理局药品审评中 心（CDE）顺利完成新药上市申请前会议（Pre-NDA）沟通交流，iza-bren用于治疗局部晚期或转移性 鼻咽癌已被CDE纳入优先审评品种名单。现将相关情况公告如下： 一、药品的基本情况 药品名称：注射用BL-B01D1/iza-bren 根据我国药品注册相关的法律法规要求，药品在获得上市申请受理后，尚需通过国家药品监督管理局相 关审评程序并获批准后方可上市、销售。 由于医药产品具有高科技、高风险、高附加值的特点，药品 ...

Suspension - Jiahua Technology is planning to acquire a controlling stake in Shudun Information Technology through a combination of share issuance and cash payment, leading to a stock suspension [1] - Kaizhong Co., Ltd. is planning a private placement to acquire control of Anhui Tuosheng Automotive Parts, resulting in a stock suspension [1] Mergers and Acquisitions - Yingli Co., Ltd. intends to use 66.497 million yuan to purchase 100% equity of Foshan Zhiqiang Optoelectronics, a supplier of PC display module structural components [2] - Aerospace Electric is planning to acquire 32% equity of Hangdian System for 46.5903 million yuan, after which Hangdian System will become a wholly-owned subsidiary [2] - Huaihe Energy plans to conduct a private placement to acquire 89.30% equity of Huainan Mining at a transaction price of 11.694 billion yuan [2] - Jinfeng Technology is in the process of planning a cash acquisition of at least 51% equity in Guangdong Lanyuan Technology [3] Share Buybacks and Equity Transfers - Hesheng New Materials will see a change in controlling shareholder to Moer Zhixin, with the actual controller changing from Zhao Dongming to Xie Haiwen [4] - Zhongwu Drone's Chengdu Industrial Investment plans to transfer 1.5% equity [5] - Changshan Pharmaceutical's shareholder Gao Shuhua intends to transfer 5.0051% equity to Element Fund at a transfer price of 46.25 yuan per share [6] External Investments and Daily Operations - Baili Tianheng's innovative drug, the EGFR×HER3 dual antibody ADC drug iza-bren, has had its market application accepted, marking a global first and unique entry into Phase III clinical trials [7] - Zhongding Co., Ltd. is collaborating with Fourier on humanoid robot-related products to promote the development of components such as harmonic reducers and planetary reducers [7] - JinkoSolar has officially launched mass production of its Tiger Neo 3.0 module, achieving a total of 15GW in signed orders with major distributors [7] - Baicheng Pharmaceutical has reached an exclusive cooperation agreement with Zhongshen Innovation for the Class 1 innovative drug BIOS-0629 project in Greater China, with a milestone payment of 300 million yuan based on R&D milestones [7] - Jindi Co., Ltd. has signed a strategic cooperation intention letter with Dongpei Industrial to collaborate on humanoid robot harmonic reducer assemblies and key components [7] - Nenghui Technology has signed a contract for a "new energy power battery assembly" with Company X, with a total estimated contract value of 10 million yuan [8] - Huibo Pu has been confirmed as the winning bidder for the Naft Khana oilfield restoration project in Iraq, with a contract amount of 225 million USD, approximately 1.596 billion yuan [8] - Guangdong Construction has won the EPC project for the Yuejianke·Zhongshan Smart Gathering Project, with a bid price of 416 million yuan [8] - Dajin Heavy Industry has signed a contract for a European offshore wind farm project, with a total contract amount of approximately 1.339 billion yuan [9] - Aerospace Development's subsidiary, Hangtian Tianmu, plans to publicly list for capital increase [10]

以下是第一财经对一些重要公告的汇总，供投资者参考。 【品大事】 佳华科技：拟购买数盾科技控股权 股票停牌 佳华科技公告，公司正在筹划以发行股份及支付现金的方式购买数盾信息科技股份有限公司的控股权并 募集配套资金，可能构成重大资产重组。公司股票自2025年11月24日起停牌，预计停牌时间不超过5个 交易日。 招商银行：招银金融资产投资有限公司获准开业 招商银行公告，全资子公司招银金融资产投资有限公司已获金融监管总局批准开业。该公司注册资本为 150亿元，将开展市场化债转股业务及股权投资试点业务。 中信银行：全资子公司信银金投获准开业 中信银行公告，国家金融监管总局已批准全资子公司信银金融资产投资有限公司（简称"信银金投"）开 业。信银金投注册资本为100亿元，注册地为广东省广州市。信银金投将围绕战略新兴产业、"专精特 新"等重点领域，开展市场化债转股及股权投资业务。 中水渔业：公司股价存在大幅上涨后回落风险 中水渔业公告，公司股票连续两个交易日收盘价涨幅偏离值累计超过20%。公司最新滚动市盈率77.53 倍，市净率为13.48倍，公司当前的市盈率、市净率与同行业平均水平有较大差异。公司近期股票交易 异常波动，可 ...

Investment Rating - The report indicates a neutral investment rating for the pharmaceutical industry, suggesting it is expected to perform in line with the overall market [24]. Core Insights - The pharmaceutical sector experienced a decline of 6.9% this week, underperforming compared to the Shanghai Composite Index, which fell by 3.9% [3][5]. - The overall valuation of the pharmaceutical sector stands at 28.9 times earnings, ranking it 10th among 31 primary sectors [5][12]. - Key events include the acceptance of a new drug application for 百利天恒's drug iza-bren, which showed promising results in clinical trials for nasopharyngeal cancer [9]. - 泽璟制药's ZG006 received FDA orphan drug designation for treating neuroendocrine cancer, demonstrating significant efficacy and safety in clinical trials [10]. - 盟科药业 decided to terminate its stock issuance plan due to disagreements among major shareholders, which may impact its operational stability [11]. Market Performance Summary - The pharmaceutical index ranked 26th among 31 sub-industries this week, with various segments showing declines, including raw materials (-8.6%) and chemical preparations (-6.8%) [3][5]. - The report highlights a focus on innovative drug sectors and medical devices, recommending specific companies for investment [2].